- Home
- WING vs RYTM Comparison
WING vs RYTM Comparison
Compare WING & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WING
- RYTM
- Stock Information
- Founded
- WING 1994
- RYTM 2008
- Country
- WING United States
- RYTM United States
- Employees
- WING N/A
- RYTM N/A
- Industry
- WING Restaurants
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- WING Consumer Discretionary
- RYTM Health Care
- Exchange
- WING Nasdaq
- RYTM Nasdaq
- Market Cap
- WING 7.8B
- RYTM 6.4B
- IPO Year
- WING 2015
- RYTM 2017
- Fundamental
- Price
- WING $251.75
- RYTM $99.92
- Analyst Decision
- WING Strong Buy
- RYTM Strong Buy
- Analyst Count
- WING 20
- RYTM 13
- Target Price
- WING $376.74
- RYTM $109.77
- AVG Volume (30 Days)
- WING 876.5K
- RYTM 612.9K
- Earning Date
- WING 11-04-2025
- RYTM 11-04-2025
- Dividend Yield
- WING 0.48%
- RYTM N/A
- EPS Growth
- WING 86.15
- RYTM N/A
- EPS
- WING 5.96
- RYTM N/A
- Revenue
- WING $669,742,000.00
- RYTM $156,287,000.00
- Revenue This Year
- WING $19.02
- RYTM $46.10
- Revenue Next Year
- WING $19.38
- RYTM $60.39
- P/E Ratio
- WING $41.81
- RYTM N/A
- Revenue Growth
- WING 22.74
- RYTM 53.55
- 52 Week Low
- WING $204.00
- RYTM $45.91
- 52 Week High
- WING $409.99
- RYTM $106.52
- Technical
- Relative Strength Index (RSI)
- WING 38.93
- RYTM 53.29
- Support Level
- WING $240.02
- RYTM $96.30
- Resistance Level
- WING $273.08
- RYTM $100.91
- Average True Range (ATR)
- WING 9.36
- RYTM 3.06
- MACD
- WING 1.99
- RYTM -0.06
- Stochastic Oscillator
- WING 38.68
- RYTM 57.47
About WING Wingstop Inc.
Founded in 1994 in Garland, Texas, Wingstop is a restaurant operator specializing in indulgent bone-in and boneless chicken wings, chicken tenders, fries, and, recently, chicken sandwiches. The firm's footprint has grown quickly since its inception, expanding to 2,818 global stores at the end of the second quarter of 2025. With a 98% franchised model, Wingstop generates the lion's share of its revenue from franchise royalties and advertising fees, with the remainder derived from a small footprint of company-owned stores.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.